Meet The Startups Of The gBETA Medtech Black Founders Accelerator 2021 Cohort
It was announced back in August that gBeta Medtech was on a mission to find Black founders for its end-of-year accelerator, and well – they found them and they’re pretty incredible.
Five healthcare startups were chosen from more than 85 applicants for the 2021 Cohort, the first gBETA Medtech program specifically for Black founders.
Each startup is receiving $34,000 in funding and “intensive, individualized coaching and access to gener8tor’s national network of mentors, customers, corporate partners, and investors.”
Here’s a list of the startups chosen:
Launched by Wendy Slone, bTECH’s disruptive wound care technology prevents lower extremity amputations from chronic non-healing wounds. bTECH’s patent-pending Halcyon Smart Patch (HSP) uses far-infrared wavelengths beneath the skin’s surface to promote rapid tissue healing and strengthening.
bTECH has developed a preliminary prototype and has recently been invited to submit an SBIR application to the National Science Foundation Medical Device division.
The health startup was founded by Nicole Bishop.
It optimizes discovery by automatically synthesizing and streaming research leads from the collective intelligence of R&D teams in real-time.
Quartolio’s proprietary algorithms synthesize insight from documents in the R&D pipeline including articles, clinical trials, and patents in the cloud regardless of document language or format. Quartolio has enterprise pilots from multiple Fortune 500 companies in the pipeline, signups of more than 1,500 scientific professionals in beta, and a partnership with IBM.
Founded by Elana Mustatea and Dr. Jossy Onwude, Bold Health delivers virtual-first integrative care to the 250M people in the US who suffer from gastrointestinal (GI) conditions and account for annual claims spend of $136B.
Bold Health’s virtual therapeutic care platform offers access to a multidisciplinary team of GI care providers and disease-specific digital therapeutic programs.
Since launching in 2018, Bold Health completed a clinical study with the University of Pennsylvania and is CE Mark and MHRA certified. Bold Health is currently finalizing a paid US pilot and has five US pilots scheduled for Q1 2022.
Delve Health‘s digital platform reduces clinical trial costs and accelerates drug development by bringing clinical trials to patient homes. Bringing a single drug to market can cost $2B+ over 10 years due to lack of enrollment, poor patient retention, and data accuracy.
It was launched by Wessam Sonbol.
Delve Health’s Clinical StudyPal is an end-to-end solution that uses mobile solutions and connected devices to make clinical trials more accessible and inclusive, and improve patient engagement and data compliance.
Since 2018, Delve Health has doubled its growth year over year, with $3.1M in sales and more than 3,000 patients enrolled. Delve Health has helped customers obtain FDA and EMA approval for one product and an oncology drug is currently pending FDA approval.
Mayo Clinic, University of Minnesota, and Medical Alley Association will provide mentorship support, while the program also receives support through a cooperative agreement with the Biomedical Advanced Research and Development Authority (BARDA) DRIVe (Division of Research, Innovation, and Ventures) initiative.
“The healthcare landscape is full of unmet needs, with millions of patients, caregivers and healthcare professionals seeking solutions to difficult problems. No single company, big or small, will have all the answers—but every step we take to strengthen our innovation ecosystem and bring new perspectives to these conversations brings us closer to meaningful solutions,” Boston Scientific VP of Global Strategy & Venture Capital Scott Davidson said in the release.